Pfizer to acquire cancer drug company Medivation
Pfizer is to acquire cancer drug company Medivation in a deal valued at about US$14bn.
Medivation is best known for cancer treatment Xtandi, which it jointly markets with Japanese drug maker Astellas Pharma.





